Entrada Therapeutics (TRDA) announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, MHRA, and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose, MAD, clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, DMD, in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio